This study targeted carbon dioxide (CO 2 ) oscillations seen in oscillatory ventilation with dynamic pre-emptive CO 2 administration.
Background
Oscillations in end-tidal CO 2 (et-CO 2 ) drive the ventilatory oscillations of periodic breathing (PB) and central sleep apnea in heart failure (HF).
Methods
Seven healthy volunteers simulated PB, while undergoing dynamic CO 2 administration delivered by an automated algorithm at different concentrations and phases within the PB cycle. The algorithm was then tested in 7 patients with HF and PB.
Results
In voluntary PB, the greatest reduction (74%, p Ͻ 0.0001) in et-CO 2 oscillations was achieved when dynamic CO 2 was delivered at hyperventilation; when delivered at the opposite phase, the amplitude of et-CO 2 oscillations increased (35%, p ϭ 0.001). In HF patients, oscillations in et-CO 2 were reduced by 43% and ventilatory oscillations by 68% (both p Ͻ 0.05). During dynamic CO 2 administration, mean et-CO 2 and ventilation levels remained unchanged. Static CO 2 (2%, constant flow) administration also attenuated spontaneous PB in HF patients (p ϭ 0.02) but increased mean et-CO 2 (p ϭ 0.03) and ventilation (by 45%, p ϭ 0.03).
Conclusions
Dynamic CO 2 administration, delivered at an appropriate time during PB, can almost eliminate oscillations in et-CO 2 and ventilation. This dynamic approach might be developed to treat central sleep apnea, as well as minimizing undesirable increases in et-CO 2 Periodic breathing (PB), Cheyne-Stokes respiration, and central sleep apnea (CSA) are frequently seen (1) oscillatory patterns in heart failure (HF), associated with a worse prognosis (1) (2) (3) . Although, these ventilatory oscillations are driven by oscillations in CO 2 (4 -6), the latter are not specifically targeted by current treatments.
Mathematical modeling (7) suggests that carefully targeting therapy within the PB cycle may fill in the troughs of end-tidal CO 2 (et-CO 2 ) that produce hypopneas, as well as minimizing any undesirable increase in et-CO 2 that could cause hyperventilation and adrenergic overactivation (8 -11) .
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We investigated this in 2 ways. First, dynamic CO 2 was administered in voluntary periodic breathing (VPB) (12, 13) at different timings and concentrations. Second, dynamic CO 2 was administered to HF patients with spontaneous PB.
Methods

Subjects.
Seven healthy subjects free of medications and 7 HF patients with daytime spontaneous PB were enrolled (Table 1 ). All HF patients were on stable contemporary treatment and free of recent decompensation, ventilatory disorders, and drugs affecting ventilatory drive. Spontaneous PB was defined as an oscillatory pattern in ventilation with a period of ϳ60 s characterized by phases of hyperventilation and central apnea (cessation of ventilatory effort for Ն10 s) or hypopnea (50% reduction in tidal volume, with Ն4% oxygen saturation) shown during a 30-min outpatient recording (1,14 -16) . All subjects gave informed consent for the study that was approved by the NHS Research Ethics Committee (05/Q0404/018). Measurements. Subjects underwent baseline recordings recumbent, breathing through a pneumotachograph (Hans Rudolph Inc., Shawnee, Kansas) attached to a Multicap (Datex Instrumentarium, Helsinki, Finland) measuring gas concentrations. They were monitored via electrocardiogram (Hewlett-Packard, Palo Alto, California), beat-by-beat blood pressure and cardiac output (Finometer, Finapres Medical Systems, Amsterdam, Netherlands). Data acquisition. Data were sampled at 1,000 Hz simultaneously from all devices using an analog-to-digital card (DAQCard 6062E, National Instruments, Austin, Texas) with LabView (version 7.0, National Instruments) and analyzed offline (17) (18) (19) . CO 2 administration system. Using a motorized valve (Fig. 1) , the system delivers CO 2 in any configuration of timing and dose. Custom software (Matlab, Natick, Massachusetts) (17-19) analyzes ventilation and computes the magnitude and the phase of ventilatory oscillations in real-time, with the ventilatory cycle represented as a clock (peak ventilation at 0°, nadir ventilation at 180°).
Dynamically titrated concentrations of CO 2 are delivered according to both magnitude and phase of the current cycle. CO 2 concentration is varied smoothly, from 0, before peak administration, rising to a brief peak level, and then declining to 0 again, in a sinusoidal shape. VPB in healthy volunteers. Voluntary PB was achieved using computer program guidance (20) . We defined the relative amplitude of oscillation (␣) as the ratio between amplitude and mean, for ventilation (␣ VEN ) and et-CO 2 (␣ ET-CO2 ). The ratio between the alpha values (e.g., ␣ ET-CO2/␣ VEN ) controls for variation in depth of ventilatory oscillations. CO 2 administration protocol. The average delay between starting the motor and gas reaching the alveolar space was ϳ7s corresponding to an angle of 40 (7/60 Ϸ 40/360). We delivered CO 2 at -40 so that CO 2 would arrive in the alveolar space coincident with peak ventilation.
In VPB, to explore the effect of the phase of CO 2 administration, we performed replicate experiments where CO 2 Data are expressed as mean Ϯ SD. ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin receptor blocker; BMI ϭ body mass index; HF ϭ heart failure; NYHA ϭ New York Heart Association.
Figure 1 Overview of the System
Representation of the system used to dynamically deliver CO 2 to the subject. The reservoir of CO 2 is maintained at atmospheric pressure, with delivery dependent on the subject's inspiration.
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or by analysis of variance with Bonferroni post hoc correction in cases of multiple comparisons with VPB where 6 different times of administration were tested and p Ͻ 0.003 was considered significant, and likewise for 3 different doses (1%, 2%, and 4%), p Ͻ 0.008.
Results
Subject characteristics.
Seven healthy subjects were enrolled (Table 1) , each of them able to consistently perform VPB (Table 2) . Seven HF patients with spontaneous PB (Table 1) were recruited, of whom 4 had apneas and 3 only hypopneas.
Impact of timing and peak dose of dynamic CO 2 administration in VPB.
The greatest reduction in size of et-CO 2 oscillations occurred when CO 2 was delivered at -40° (  Fig. 2) , which is a 74% reduction below baseline (0.05 Ϯ 0.02 kPa vs. 0.20 Ϯ 0.03 kPa, p Ͻ 0.0001).
The other phases of CO 2 delivery were less effective in attenuating et-CO 2 oscillations. Efficiency declined progressively as the treatment angle was moved from -40°. In the extreme (180°away from -40°, approximately trough ventilation), oscillations were 35% larger than at baseline (0.27 Ϯ 0.05 kPa vs. 0.20 Ϯ 0.03 kPa, p ϭ 0.001) (Fig. 2) .
Dynamic CO 2 with peak concentration of 2% was more effective than 1% in attenuating et-CO 2 oscillations (0.05 Ϯ 0.02 vs. 0.13 Ϯ 0.03, p Ͻ 0.001). However, a peak concentration higher than 2% did not further reduce et-CO 2 oscillations (0.05 Ϯ 0.01 vs. 0.05 Ϯ 0.02, p ϭ 0.47) (Fig. 3) . Dynamic CO 2 administration in HF patients with spontaneous PB. When CO 2 was delivered coincident with peak ventilation, et-CO 2 oscillations were reduced by 43% (SD Ϭ mean: 0.07 Ϯ 0.03 untreated vs. 0.04 Ϯ 0.02 treated Example of 1 patient with heart failure and daytime Cheyne-Stokes respiration efficaciously treated with dynamic CO 2 . The delivery of 2% CO 2 (peak dose) at 0°with an angle width of delivery ranging from -90°to ϩ140°was able to abolish not only the oscillations in end-tidal CO 2 , but also the fluctuations in ventilation, without increasing their average values. HF ϭ heart failure; PB ϭ periodic breathing. In no patient did dynamic CO 2 increase ectopy, a marker of sympathetic activity (21) . There were fewer ectopics in Patients #3 and #4 (from 37 to 14, and from 18 to 0 per 10-min recording, respectively).
Effect of VPB in Healthy Volunteers on Ventilatory and Hemodynamic Parameters
Discussion
This study demonstrates the possibility of attenuating CO 2 oscillations that drive PB using dynamically timed CO 2 administration. However, timing is critical, the most efficacious administration being coincident with peak ventilation.
Because CO 2 is only delivered for a small part of the PB cycle, the total quantity of CO 2 delivered is markedly reduced, thus minimizing unwanted consequences of increased et-CO 2 , such as increased mean ventilation and sympathetic overactivation (8 -11) . Periodic breathing and CO 2 . Frequently in HF, with either preserved or reduced systolic function (1, 22) , the chemoreflex is enhanced and delayed (6, 23) . In CSA, there may be sleep disruption, fatigue, adrenergic overactivation (24) , and increased mortality (2) . Delivery of static CO 2 is efficacious in abolishing CSA (8, 9) , by increasing eupneic CO 2 when wakefulness drive is lost (25) , but creates undesirable elevations in mean ventilation and sympathetic activity (8 -11) . With dynamic CO 2 , the average dose of CO 2 delivered is lower (0.5%), compared with static CO 2 (2%), but achieves a 67% and 43% reduction in et-CO 2 oscillations in VPB and spontaneous PB, respectively. There is a nonsignificant trend toward higher et-CO 2 in the treatment group, but the numerical size is much smaller than that seen with static administration. Moreover, this may be of less significance given the positive effects on oxygen saturation. CO 2 administration may not only increase the eupneic CO 2 , but may beneficially lower pulmonary capillary wedge pressure via vasodilation (26) .
The minimization of dose was achieved using the following strategy:
1. CO 2 was only delivered for a portion of the PB cycle. 2. Delivery was gradually built up within each cycle. 3. Peak delivery was dependent on magnitude of ventilatory oscillations.
Because breathing may only be periodic for a portion of sleep time, this algorithm would deliver CO 2 only during oscillations. The algorithm was successful in both groups despite spontaneous PB being more variable from cycle to cycle than VPB, which has experimentally enforced regularity (27) . Clinical implications. This might be developed for CSA if facemasks (which are often rejected in clinical practice) (28) were replaced with nasal cannulas and the pneumotachograph by an alternative ventilation sensor. Study limitations. Larger studies that go beyond this proof-of-concept to evaluate sleep architecture are needed to examine the effect of this administration on CSA in HF patients and to assess whether CSA is converted to obstructive sleep apnea (29) .
Conclusions
This study demonstrates that dynamic CO 2 administration, when given at the right time, almost abolishes the oscillations in et-CO 2 that drive PB. This administration is found to be most effective when CO 2 arrives in the alveoli coincident with hyperventilation. Our results with dynamic CO 2 intervention support the concept of apneas and hypopneas arising from pathological hypocapnia and may offer an opportunity to develop therapies for PB and CSA that might avoid some of the pitfalls of static CO 2 administration.
